{"id":86668,"date":"2025-03-25T08:28:18","date_gmt":"2025-03-25T07:28:18","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/"},"modified":"2025-03-25T08:28:18","modified_gmt":"2025-03-25T07:28:18","slug":"celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/","title":{"rendered":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos"},"content":{"rendered":"<p>Un grupo investigador espa\u00f1ol, liderado por la Cl\u00ednica Universidad de Navarra (CUN) y el CIEMAT, ha desarrollado un nuevo tipo de c\u00e9lulas CAR-T basadas en vectores no virales y dirigidas al tratamiento de c\u00e1nceres hematol\u00f3gicos como los linfomas o leucemias de linfocitos B. Esta terapia innovadora se basa en la modificaci\u00f3n gen\u00e9tica de linfocitos T del paciente para reconocer y atacar las c\u00e9lulas malignas que presentan en su superficie el ant\u00edgeno CD19.<\/p>\n<p>Las nuevas c\u00e9lulas CAR-T se han generado con un sistema de vectores no virales que emplea el transpos\u00f3n terap\u00e9utico &#8216;Sleeping Beauty&#8217; y una mol\u00e9cula transposasa que facilita su integraci\u00f3n en el ADN de los linfocitos T del paciente.<\/p>\n<p>Esta herramienta de terapia g\u00e9nica permite introducir nuevos genes en las c\u00e9lulas diana de forma segura y eficaz. Seg\u00fan Felipe Pr\u00f3sper, director del \u00c1rea de Terapia Celular de la CUN y jefe de grupo del CIBERONC, \u201cel componente innovador radica en que hemos empleado un sistema de transposones para introducir el CAR dentro de las c\u00e9lulas T, en lugar de vectores virales. Si logramos confirmar la eficacia antitumoral de estas c\u00e9lulas CAR-T en pacientes, podr\u00edamos estar hablando de numerosas ventajas en t\u00e9rminos de costes, seguridad y facilidad de producci\u00f3n\u201d.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png\" \/><\/p>\n<p>Si logramos confirmar la eficacia antitumoral de estas c\u00e9lulas CAR-T en pacientes, podr\u00edamos obtener numerosas ventajas en t\u00e9rminos de costes, seguridad y facilidad de producci\u00f3n<\/p>\n<p> Felipe Pr\u00f3sper (Cl\u00ednica Universitaria de Navarra)<br \/>\n<img decoding=\"async\" src=\"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quoteafter.png\" \/><\/p>\n<p>Para generar estas c\u00e9lulas CAR-T, los linfocitos T extra\u00eddos del paciente se electropermeabilizan para facilitar la inserci\u00f3n del complejo terap\u00e9utico transpos\u00f3n\/transposasa sin necesidad de utilizar vectores virales, lo que reduce los costes de producci\u00f3n a una quinta o d\u00e9cima parte.<\/p>\n<p>\u201cNo podemos olvidar que, en la actualidad, una de las limitaciones de la terapia g\u00e9nica radica en su muy elevado coste. De ah\u00ed que propusi\u00e9ramos el inicio de un nuevo proyecto cuyos resultados de seguridad y eficacia se han publicado en la revista Molecular Therapy Methods and Clinical Developments\u201d, indica Juan Bueren, director de la Unidad de Innovaci\u00f3n Biom\u00e9dica del CIEMAT.<\/p>\n<p><a><\/a><\/p>\n<h2>Ensayo en pacientes<\/h2>\n<p>El proceso de fabricaci\u00f3n ya ha sido aplicado a escala cl\u00ednica en las Salas Blancas del CIMA y del CIEMAT, cumpliendo con los\u00a0est\u00e1ndares de calidad requeridos para su uso en pacientes. En modelos experimentales ha demostrado una eficacia y seguridad comparables a las obtenidas con vectores virales, mucho m\u00e1s costosos.<\/p>\n<p>En modelos experimentales, ha demostrado una eficacia y seguridad comparables a las obtenidas con vectores virales, mucho m\u00e1s costosos<\/p>\n<p>Con estos resultados, la Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios ha autorizado el desarrollo de un ensayo cl\u00ednico pionero para el tratamiento de pacientes con linfomas de tipo B. El estudio, promovido por el Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), cuenta con la colaboraci\u00f3n de varios centros de la Red Espa\u00f1ola de Terapias Avanzadas y su inclusi\u00f3n en los Proyectos de Investigaci\u00f3n Cl\u00ednica Independiente del Instituto de Salud Carlos III. \u201cEl objetivo inicial del ensayo cl\u00ednico es demostrar la seguridad del tratamiento, si bien confiamos en mostrar evidencias iniciales de eficacia antitumoral\u201d, se\u00f1ala Ferm\u00edn S\u00e1nchez-Guijo, jefe del Servicio del Hospital Cl\u00ednico de Salamanca.<\/p>\n<p>Referencia:<\/p>\n<p>\u00abGeneration and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances\u00bb. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40034423\/\" target=\"_blank\">Molecular Therapy. Methods &amp; Clinical Therapy<\/a>\u00a0(2025)<\/p>","protected":false},"excerpt":{"rendered":"<p>Un grupo investigador espa\u00f1ol, liderado por la Cl\u00ednica Universidad de Navarra (CUN) y el CIEMAT, ha desarrollado un nuevo tipo de c\u00e9lulas CAR-T basadas en vectores no virales y dirigidas al tratamiento de c\u00e1nceres hematol\u00f3gicos como los linfomas o leucemias de linfocitos B. Esta terapia innovadora se basa en la modificaci\u00f3n gen\u00e9tica de linfocitos T [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-86668","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos\" \/>\n<meta property=\"og:description\" content=\"Un grupo investigador espa\u00f1ol, liderado por la Cl\u00ednica Universidad de Navarra (CUN) y el CIEMAT, ha desarrollado un nuevo tipo de c\u00e9lulas CAR-T basadas en vectores no virales y dirigidas al tratamiento de c\u00e1nceres hematol\u00f3gicos como los linfomas o leucemias de linfocitos B. Esta terapia innovadora se basa en la modificaci\u00f3n gen\u00e9tica de linfocitos T [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T07:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos\",\"datePublished\":\"2025-03-25T07:28:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.agenciasinc.es\\\/bundles\\\/app\\\/images\\\/quotebefore.png\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/\",\"name\":\"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.agenciasinc.es\\\/bundles\\\/app\\\/images\\\/quotebefore.png\",\"datePublished\":\"2025-03-25T07:28:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.agenciasinc.es\\\/bundles\\\/app\\\/images\\\/quotebefore.png\",\"contentUrl\":\"https:\\\/\\\/www.agenciasinc.es\\\/bundles\\\/app\\\/images\\\/quotebefore.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/","og_locale":"es_ES","og_type":"article","og_title":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos","og_description":"Un grupo investigador espa\u00f1ol, liderado por la Cl\u00ednica Universidad de Navarra (CUN) y el CIEMAT, ha desarrollado un nuevo tipo de c\u00e9lulas CAR-T basadas en vectores no virales y dirigidas al tratamiento de c\u00e1nceres hematol\u00f3gicos como los linfomas o leucemias de linfocitos B. Esta terapia innovadora se basa en la modificaci\u00f3n gen\u00e9tica de linfocitos T [&hellip;]","og_url":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/","og_site_name":"bip4ex","article_published_time":"2025-03-25T07:28:18+00:00","og_image":[{"url":"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos","datePublished":"2025-03-25T07:28:18+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/"},"wordCount":609,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#primaryimage"},"thumbnailUrl":"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/","url":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/","name":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#primaryimage"},"thumbnailUrl":"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png","datePublished":"2025-03-25T07:28:18+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#primaryimage","url":"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png","contentUrl":"https:\/\/www.agenciasinc.es\/bundles\/app\/images\/quotebefore.png"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/celulas-car-t-mas-versatiles-y-economicas-para-tratar-canceres-hematologicos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"C\u00e9lulas CAR-T m\u00e1s vers\u00e1tiles y econ\u00f3micas para tratar c\u00e1nceres hematol\u00f3gicos"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/86668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=86668"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/86668\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=86668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=86668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=86668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}